

1 ***Inferring Multi-Organ Genetic Causal Connections using Imaging and Clinical Data***
2 ***through Mendelian Randomization***

3

4 **Running title: MR atlas for multi-organ images**

5

6 Juan Shu¹, Rong Zheng², Carlos Copana¹, Bingxuan Li³, Zirui Fan^{1,4}, Xiaochen Yang¹, Yilin Yang⁵,
7 Xiyao Wang³, Yujue Li¹, Bowei Xi¹, Tengfei Li^{6,7}, Hongtu Zhu^{8,9,10,11*}, and Bingxin Zhao^{1,4*}

8

9 ¹Department of Statistics, Purdue University, West Lafayette, IN 47907, USA.

10 ²Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001,
11 China.

12 ³Department of Computer Science, Purdue University, West Lafayette, IN 47907, USA.

13 ⁴Department of Statistics and Data Science, University of Pennsylvania, Philadelphia, PA 19104, USA.

14 ⁵Department of Computer and Information Science and Electrical and Systems Engineering, School of
15 Engineering & Applied Science, University of Pennsylvania, Philadelphia, PA 19104, USA.

16 ⁶Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

17 ⁷Biomedical Research Imaging Center, School of Medicine, University of North Carolina at Chapel Hill,
18 Chapel Hill, NC 27599, USA.

19 ⁸Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

20 ⁹Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

21 ¹⁰Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

22 ¹¹Department of Statistics and Operations Research, University of North Carolina at Chapel Hill, Chapel Hill,
23 NC 27599, USA.

24

25 **Corresponding authors:*

26 Hongtu Zhu

27 3105C McGavran-Greenberg Hall, 135 Dauer Drive, Chapel Hill, NC 27599.

28 E-mail address: htzhu@email.unc.edu Phone: (919) 966-7250

29

30 Bingxin Zhao

31 413 Academic Research Building, 265 South 37th Street, Philadelphia, PA 19104.

32 E-mail address: bxzhao@upenn.edu Phone: (215) 898-8222

1 **Abstract**

2 Deciphering the complex causal relationships between multiple organs and major clinical
3 outcomes and the causal interplay among multiple organs remains a significant challenge.
4 By utilizing imaging biomarkers, we can characterize the functional and structural
5 architectures of major human organs. Mendelian randomization (MR) provides a valuable
6 framework for inferring causality by leveraging genetic variants as instrumental variables.
7 In this study, we conducted a systematic multi-organ MR analysis involving 402 imaging
8 biomarkers and 88 clinical outcomes. Our analysis revealed 488 genetic causal links for 62
9 diseases and 130 imaging biomarkers across various organs, tissues, and systems,
10 including the brain, heart, liver, kidney, lung, pancreas, spleen, adipose tissue, and
11 skeletal system. We specifically focused on critical intra-organ causal connections, such
12 as the bidirectional genetic links between Alzheimer's disease and brain function, as well
13 as inter-organ causal effects, such as the detrimental impact of heart diseases on brain
14 health. These findings shed light on the genetic causal links spanning multiple organs,
15 contributing to a deeper understanding of the intricate relationships between organ
16 imaging biomarkers and clinical outcomes. Our multi-organ MR results can be explored
17 at <https://mr4mo.org/>.

18

19 **Keywords:** Brain imaging; Clinical outcomes; FinnGen; GWAS; Heart imaging; Mendelian
20 randomization; MRI; Organ imaging; UK Biobank.

1 Medical imaging techniques such as magnetic resonance imaging (MRI) measure the
2 structure and function of many human organs, such as the brain, heart, liver, and kidney.
3 Their derived imaging biomarkers have found widespread use in both clinical research
4 and practical applications. For example, structural and functional imaging biomarkers
5 extracted from brain MRIs have consistently revealed abnormalities associated with
6 Alzheimer's disease, particularly within the hippocampal region¹. Cardiovascular MRI
7 (CMR) provides insights into changes in ventricular function, cardiovascular structure, and
8 myocardial perfusion, all of which are intricately linked to cardiovascular diseases².
9 Furthermore, skeletal Dual-Energy X-ray Absorptiometry (DXA) aids in identifying novel
10 genetic variants that influence the human skeletal structure, thereby revealing significant
11 evolutionary trends in human anatomical changes leading to pathogenesis³. Several large-
12 scale organ imaging datasets (on the scale of over 10,000 participants) have recently been
13 made publicly available, revealing details about human organ structure and function⁴⁻⁸. A
14 multitude of complex traits and clinical outcomes have been found to associate with
15 organ imaging biomarkers, as evidenced by these robust, population-based studies^{9,10}.
16 Despite these advances, inherent limitations in observational data pose challenges in
17 definitively establishing causal relationships between imaging biomarkers and clinical
18 outcomes, as well as in gaining a comprehensive understanding of the causal interplay
19 across various organs¹¹. Mendelian randomization (MR) utilizes genetic variants as
20 instrumental variables to infer causality from observational data^{12,13}. Operating under
21 certain assumptions regarding genetic, exposure, and outcome variables, MR seeks to
22 uncover causal relationships between exposure and outcome variables, while controlling
23 for confounding factors. Both family and population-based studies have demonstrated
24 that numerous imaging biomarkers and complex diseases are profoundly influenced by
25 genetics. Hundreds of associated genetic loci have been pinpointed in large-scale
26 genome-wide association studies (GWAS)^{8,14-29}. By utilizing these GWAS summary-level
27 data (summary statistics), MR methods can unveil causal relationships between imaging
28 measurements and clinical outcomes. Numerous recent MR studies have explored the
29 genetic causality of imaging biomarkers^{11,30-35}. However, a common limitation of these
30 MR studies is their focus on a single organ (or imaging modality) and/or a single disease,
31 or diseases in a specific domain, such as brain imaging and psychiatric disorders³⁰. It is
32 crucial to note, though, that many diseases act as the causes and/or consequences of

1 functional and structural changes in various organs of the human body. Cross-organ
2 analysis can elucidate the complexity of human physiology, subsequently improving our
3 capacity to diagnose, treat, and prevent a multitude of diseases. Consequently, it is
4 essential to conduct MR analysis from a multi-organ perspective to comprehend the
5 clinical implications of imaging biomarkers amidst the complex interrelationships of organ
6 systems.

7

8 In this paper, we carried out a systematic two-sample MR analysis to explore the causal
9 relationships between multi-organ imaging and clinical endpoints. We consolidated
10 GWAS summary statistics from 402 multi-organ imaging biomarkers (with an average
11 sample size $n \approx 35,000$) from the UK Biobank (UKB)³⁶ study along with 88 clinical outcomes
12 (each with more than 10,000 cases) sourced from the FinnGen project²⁷ (**Fig. S1** and
13 **Tables S1-S2**). Our focus was on three major brain MRI modalities: 1) 101 regional brain
14 volumes²¹ from structural MRI (sMRI); 2) 110 diffusion tensor imaging (DTI) parameters²³
15 from diffusion MRI (dMRI); and 3) 90 functional activity (amplitude³⁷) and connectivity
16 traits from functional MRI (fMRI)²⁵. Furthermore, we incorporated 82 CMR traits
17 extracted from short-axis, long-axis, and aortic cine cardiac MRI^{38,39}. We also considered
18 11 abdominal MRI biomarkers, measuring volume, fat, or iron content in seven organs
19 and tissues⁸, and eight DXA imaging biomarkers that gauged the lengths of all long bones
20 and the width of the hip and shoulder²⁹. We applied 8 MR methods⁴⁰⁻⁴⁸ to investigate
21 bidirectional genetic causal links. The study design is presented in **Figure 1A**, while **Figure**
22 **1B** offers a high-level summary of our key findings. Additional details on these multi-organ
23 imaging biomarkers are provided in the Methods section. We have made our database
24 publicly available and developed a browser framework to facilitate the exploration of
25 multi-organ MR findings (<http://mr4mo.org/>).

26

27 **RESULTS**

28 **Genetic causality between brain imaging and multi-organ diseases**

29 We explored the causal relationship between brain imaging biomarkers and multi-organ
30 diseases. At the Bonferroni significance level ($P < 5.18 \times 10^{-6}$, multiple testing adjustment
31 for both directions), MR highlighted 127 significant genetic causal effects on 58 brain
32 imaging biomarkers stemming from 20 diseases in 8 major categories. These categories

1 include mental and behavioral disorders, diseases of the nervous system, diseases of the
2 circulatory system, cardiometabolic endpoints, interstitial lung disease endpoints,
3 diseases marked as autoimmune origin, diseases of the eye and adnexa, and diseases of
4 the genitourinary system (**Fig. S2** and **Table S3**). Heart-related diseases were the most
5 frequent (66/127) and were predominantly linked to DTI parameters and a smaller set of
6 regional brain volumes. We did not observe significant causal effects from heart diseases
7 to fMRI traits. The top three heart diseases demonstrating causal genetic influences on
8 brain structures were peripheral artery disease (15/66), hypertension (14/66), and
9 hypertensive diseases (12/66) (**Figs. S2-S4**). For example, peripheral artery disease
10 causally impacted the white matter microstructure within the anterior limb of the internal
11 capsule (ALIC, $|\beta| > 0.15$, $P < 3.04 \times 10^{-8}$), the body of corpus callosum tract (BCC, $|\beta| > 0.14$,
12 $P < 8.44 \times 10^{-7}$), and the genu of corpus callosum tract (GCC, $|\beta| > 0.13$, $P < 4.24 \times 10^{-6}$).
13 Hypertension and hypertensive diseases causally affected the superior corona radiata
14 (SCR, $|\beta| > 0.07$, $P < 9.47 \times 10^{-8}$). Beyond DTI parameters, hypertension also negatively
15 impacted the total grey matter volume ($|\beta| > 0.02$, $P < 1.26 \times 10^{-8}$) (**Figs. 2C** and **S2-S3**). In
16 addition to heart-related diseases, several other non-neurological clinical endpoints also
17 influenced brain health. For example, asthma had negative causal effects on the SCR
18 ($|\beta| > 0.05$, $P < 7.26 \times 10^{-7}$) and the volume of the right inferior lateral ventricle ($|\beta| > 0.09$,
19 $P < 8.66 \times 10^{-7}$) (**Fig. S5**).

20
21 Brain disorders also demonstrated causal effects on brain imaging biomarkers (49/127),
22 with dementia and Alzheimer's disease emerging as the most common brain-related
23 diseases (**Fig. S2**). Intriguingly, brain disorders are primarily linked to fMRI traits. For
24 example, Alzheimer's disease consistently exhibited a causal relationship with decreased
25 functional activity in the dorsal attention ($|\beta| > 0.04$, $P < 5.07 \times 10^{-8}$), frontoparietal, and
26 secondary visual network ($|\beta| > 0.04$, $P < 4.70 \times 10^{-8}$), as well as DTI parameters of the SCR
27 ($|\beta| > 0.03$, $P < 1.85 \times 10^{-6}$) (**Figs. 2A** and **S6**). Both functional MRI and DTI parameters have
28 been widely used in Alzheimer's disease research⁴⁹. White matter abnormalities, such as
29 those in the left SCR, and decreased functional connectivity in attention-related networks,
30 have been identified in patients with Alzheimer's disease^{50,51}. Similar to Alzheimer's
31 disease, dementia showed negative causal genetic effects on functional activity in
32 multiple networks, including the cingulo-opercular, default mode, dorsal attention,

1 frontoparietal, language, posterior multimodal, and secondary visual networks ($|\beta| > 0.12$,
2 $P < 4.74 \times 10^{-8}$) (**Figs. 2B and S7**). Additionally, mood disorders affected brain volume traits,
3 such as the left and right putamen ($|\beta| > 0.04$, $P < 5.64 \times 10^{-7}$) (**Fig. S8**). A more
4 comprehensive summary of causal genetic links from clinical endpoints to brain imaging
5 biomarkers can be found in **Figures S3-S9**.

6

7 Brain and other organ-related diseases may also be caused by structural or functional
8 changes in the brain. To investigate this, we used brain imaging biomarkers as exposure
9 variables and clinical endpoints as the outcome variables. At the Bonferroni significance
10 level ($P < 5.18 \times 10^{-6}$), we identified 85 significant relationships between 22 brain imaging
11 biomarkers and 20 clinical endpoints (**Fig. S10 and Table S3**). Most of the significant
12 imaging-disease pairs were related to fMRI traits. Specifically, 66 of the 85 pairs were
13 linked to fMRI traits, 10 to DTI parameters, and 9 to regional brain volumes. The majority
14 of the significant findings pertained to brain diseases (65/85), with a minor proportion
15 linked to heart diseases (13/85), autoimmune diseases (4/85), COPD and related
16 endpoints (1/85), diseases of the eye and adnexa (1/85), and diseases of the genitourinary
17 system (1/85). For example, we found that reduced activity in several functional networks
18 correlated with an increased risk of Alzheimer's disease, such as the default mode and
19 dorsal-attention networks ($|\beta| > 0.5$, $P < 5.65 \times 10^{-13}$) (**Figs. 3A and S11**). Additionally,
20 genetic causal effects from DTI parameters on Alzheimer's disease were identified, such
21 as those related to the BCC and SCR ($|\beta| > 0.49$, $P < 6.79 \times 10^{-7}$) (**Figs. 3A and S11**).

22

23 Dementia exhibited a pattern similar to Alzheimer's disease, being causally influenced by
24 decreased activity in multiple networks, such as the default mode, dorsal-attention, and
25 secondary visual network ($|\beta| > 0.002$, $P < 2.77 \times 10^{-7}$) (**Fig. 3B and S12**). Other brain
26 diseases, such as neuropsychiatric disorders ($|\beta| > 0.09$, $P < 8.88 \times 10^{-16}$) and neurological
27 diseases ($|\beta| > 0.06$, $P < 1.72 \times 10^{-6}$) were also found to be causally linked to fMRI traits,
28 including the functional activity of the secondary visual network and functional
29 connectivity of the default mode network (**Figs. S13 and S14**). Finally, we discovered that
30 alterations in brain structure may also impact other non-neurological diseases. For
31 example, the left basal forebrain exhibited a negative causal effect on hypertensive
32 diseases ($|\beta| > 0.12$, $P < 8.47 \times 10^{-9}$) and hypertension ($|\beta| > 0.15$, $P < 6.19 \times 10^{-11}$).

1 Additionally, the left lingual was found to negatively influence female genital prolapse
2 ($|\beta| > 0.75$, $P < 8.68 \times 10^{-7}$).

3 **Causal genetic relationships between CMR traits and clinical outcomes**

4 We first assessed the causal effects from clinical endpoints to CMR measures of heart
5 structure and function. We identified 111 significant results at the Bonferroni significance
6 level ($P < 6.85 \times 10^{-6}$), encompassing 41 unique CMR traits of the ascending aorta (AAo),
7 descending aorta (DAo), left atrium (LA), and left ventricle (LV). These significant causal
8 effects were identified from 13 unique clinical endpoints in three categories: diseases of
9 the circulatory system (8/13), cardiometabolic endpoints (4/13), as well as COPD and
10 related endpoints (1/13). Most significant findings were linked to heart-related diseases,
11 with 66 out of 111 associated with diseases of the circulatory system and 44 out of 111
12 tied to cardiometabolic endpoints (**Fig. S15** and **Table S4**).

13

14 The most frequently occurring genetic effects were linked to hypertensive diseases and
15 hypertension (**Figs. 4A** and **S16**). Specifically, hypertensive diseases exerted negative
16 causal impacts on AAo and DAo distensibility ($|\beta| > 0.10$, $P < 1.26 \times 10^{-7}$), associations of
17 which have been identified in prior studies⁵²⁻⁵⁴. Hypertensive diseases also influenced LV
18 and LA traits, such as the global radial strain ($|\beta| > 0.06$, $P < 4.47 \times 10^{-9}$), LA stroke volume
19 ($|\beta| > 0.07$, $P < 3.04 \times 10^{-8}$), and LV myocardial mass ($|\beta| > 0.11$, $P < 3.04 \times 10^{-15}$, and see **Fig.**
20 **4B**). These findings align with findings from previous genetic association studies^{55,56}.
21 Hypertension exhibited a similar pattern to hypertensive diseases, causing impacts on
22 various AAo and DAo traits, like DAo distensibility, and LA and LV traits, such as the LA
23 minimum volume (LA_{min} volume, $|\beta| > 0.03$, $P < 7.11 \times 10^{-6}$, and see **Fig. 4C**).

24

25 Moreover, angina pectoris was found to causally influence the AAo maximum and
26 minimum areas (AAo_{max} and AAo_{min} areas, $|\beta| > 0.71$, $P < 1.44 \times 10^{-7}$). Aortic aneurysm
27 positively affected the DAo maximum and minimum areas (DAo_{max} and DAo_{min} areas,
28 $|\beta| > 0.71$, $P < 1.63 \times 10^{-24}$) as well as AAo_{max} and AAo_{min} areas ($|\beta| > 0.16$, $P < 2.22 \times 10^{-6}$),
29 aligning with clinical observations. Atrial fibrillation and flutter primarily impacted LA
30 traits, such as the LA ejection fraction ($|\beta| > 0.07$, $P < 5.88 \times 10^{-8}$), LA maximum volume
31 (LA_{max} volume, $|\beta| > 0.07$, $P < 1.62 \times 10^{-6}$), and LA_{min} volume ($|\beta| > 0.08$, $P < 8.26 \times 10^{-8}$).
32 Notably, atrial fibrillation is often linked to a decrease in ejection fraction and an increase

1 in LA volumes^{57,58}. Apart from heart-related diseases, COPD and related endpoints were
2 found to influence CMR traits. Specifically, COPD had a negative effect on DAO_{max} area
3 ($|\beta| > 0.10$, $P < 4.45 \times 10^{-11}$, and see **Fig. S16**). Emphysema, a variant of COPD characterized
4 by the deterioration of lung tissue, could contribute to the dilatation of the thoracic
5 aorta⁵⁹. This could be due to emphysema's role in damaging elastic fibers in the lungs,
6 which could then lead to changes in the elasticity of the aortic wall⁶⁰. Such alternations
7 could cause the thoracic aorta to dilate or balloon, thus increasing the risk of both aortic
8 aneurysm and abdominal aortic abnormalities⁵⁹. These findings help elucidate the
9 potential biological mechanisms driving these causal relationships.

10

11 Alternatively, structural and functional abnormalities within the heart may escalate the
12 risk of multi-organ diseases, considering the heart's role in pumping blood to all other
13 organs to sustain their functions⁶¹. We examined this direction by treating CMR traits as
14 exposure variables and clinical endpoints as the outcomes. After Bonferroni adjustment
15 ($P < 6.85 \times 10^{-6}$), we identified 27 significant causal pairs, 25 related to heart-related
16 diseases and 2 to autoimmune diseases (**Figs. 4D-G, S17, and Table S4**). For example, the
17 global peak circumferential strain was positively correlated with heart failure and
18 antihypertensive medication use ($|\beta| > 0.51$, $P < 8.49 \times 10^{-8}$), whereas the LV ejection
19 fraction exerted a negative causal effect on these conditions ($|\beta| > 0.55$, $P < 1.12 \times 10^{-6}$). In
20 addition to heart-related diseases, heart structural alternations also influenced diseases
21 of autoimmune origin. For example, the right ventricular end-systolic volume negatively
22 affected autoimmune diseases as defined by FinnGen²⁷ ($|\beta| > 0.18$, $P < 3.10 \times 10^{-6}$) (**Figs.**
23 **4D and S18**). In summary, we discovered causal relationships between CMR traits and
24 heart-related diseases, which generally exhibited bidirectionality. Furthermore, we
25 elucidated the inter-organ causal relationships between the heart and other organs.

26

27 **Causal genetic links between abdominal imaging biomarkers and clinical outcomes**

28 We first investigated the impact of multi-organ diseases on abdominal imaging
29 biomarkers, encompassing the volume or iron content of organs like the spleen, kidney,
30 liver, lung, and pancreas⁸. At the Bonferroni significance level ($P < 6.69 \times 10^{-5}$), we
31 identified 51 significant causal pairs from multi-organ diseases to abdominal imaging
32 biomarkers. Among these, liver imaging biomarkers were the most affected (26/51).

1 Brain-related diseases emerged as the most common in all significant findings (35/51),
2 succeeded by heart-related diseases (7/51), rheumatoid endpoints (4/51), diseases of the
3 eye and adnexa (3/51), and autoimmune diseases (2/51) (**Figs. 5A-E, S19, and Table S5**).
4 These findings corroborated ongoing research concerning the interplay between the
5 brain and abdominal organs, such as the brain-gut connection⁶²⁻⁶⁴, brain-kidney
6 connection^{65,66}, and brain-liver connection⁶⁷.

7
8 Alzheimer's disease and dementia were consistently observed to have causal
9 relationships with various abdominal imaging biomarkers, such as the percent liver fat
10 ($|\beta| > 0.37$, $P < 4.96 \times 10^{-6}$), liver volume ($|\beta| > 0.03$, $P < 5.88 \times 10^{-5}$), and adipose tissue
11 measurement ($|\beta| > 0.06$, $P < 3.13 \times 10^{-5}$, and see **Figs. 5A and 5C**). Apart from Alzheimer's
12 disease and dementia, several other brain-related diseases were found to potentially
13 affect abdominal organs. These included mental and behavioral disorders due to alcohol
14 and psychoactive substance use, and sleep apnoea. For example, sleep apnoea impacted
15 various abdominal traits, such as the liver volume ($|\beta| > 0.11$, $P < 2.80 \times 10^{-5}$) and kidney
16 volume ($|\beta| > 0.23$, $P < 2.57 \times 10^{-6}$, and see **Fig. 5B**). Sleep apnoea may contribute to renal
17 damage via mechanisms such as ischemic stress, hemodynamic changes, or intermediary
18 conditions like hypertension, which may result in early chronic kidney disease^{68,69}. Several
19 heart-related diseases also genetically influenced abdominal organs. For example, heart
20 failure and the use of antihypertensive medication could lead to an increase in spleen
21 volume ($|\beta| > 0.004$, $P < 2.66 \times 10^{-6}$). It's well-established that heart splenic enlargement
22 often results from blood stasis and right heart disease frequently coincides with
23 splenomegaly⁷⁰. Atherosclerosis was found to be causally linked to pancreas iron content,
24 a finding also supported by clinical evidence^{71,72}.

25
26 Beyond brain and heart-related diseases, we also observed causal effects from other
27 diseases, such as autoimmune diseases on spleen volume and liver iron content. The
28 spleen, as the largest immune organ in the body, may become enlarged due to various
29 rheumatic and immune system diseases including systemic lupus erythematosus, Felty's
30 syndrome, sarcoidosis, and autoimmune hepatitis⁷³⁻⁷⁶. We found a causal connection
31 between liver iron content and both autoimmune and rheumatological diseases
32 ($|\beta| > 0.10$, $P < 3.02 \times 10^{-5}$). Excessive iron ions have been observed to deposit in tissues

1 affected by autoimmune diseases, such as brain tissues of multiple sclerosis patients and
2 the synovial fluid of patients with rheumatoid arthritis⁷⁷. Additionally, we observed
3 disorders of the choroid and retina, along with the eye and adnexa diseases, to be causally
4 connected to liver iron content ($|\beta| > 0.10$, $P < 6.48 \times 10^{-5}$, and refer to **Figs. 5A** and **S20**).
5 Metal, including iron, tends to accumulate in human ocular tissues, notably in the choroid
6 and retinal pigment epithelium⁷⁸.

7

8 Next, we tested the opposite direction that abdominal imaging biomarkers as exposure
9 variables and multi-organ diseases as outcomes. At the Bonferroni significance level ($P <$
10 6.69×10^{-5}), we identified 55 significant pairs, with heart-related diseases being the most
11 common (34/55). These were followed by brain-related diseases (11/55), diseases
12 marked as autoimmune origin (2/55), diseases of the eye and adnexa (5/55), and diseases
13 of the genitourinary system (3/55) (**Figs. 5D-E**, **S21**, and **Table S5**). For example, pancreas
14 fat was found to have a causal impact on deep vein thrombosis of the lower extremities
15 and pulmonary embolism ($|\beta| > 0.38$, $P < 1.04 \times 10^{-12}$). Reduction in pancreatic fat content
16 might directly enhance cellular function and insulin secretion rate, which could influence
17 triglyceride levels and blood flow⁷⁹. Consequently, we found that larger liver, spleen, and
18 kidney volumes were all causally linked to heart-related diseases (**Figs. 5D** and **S22**).
19 Specifically, a larger liver volume was causally linked to hypertensive diseases and
20 hypertension ($|\beta| > 0.13$, $P < 1.19 \times 10^{-10}$); a larger kidney volume was causally related to
21 an increased risk of stroke ($|\beta| > 0.25$, $P < 3.33 \times 10^{-5}$); and a larger spleen volume had
22 causal effects on a range of heart-related diseases, including coronary angioplasty
23 ($|\beta| > 0.14$, $P < 4.94 \times 10^{-7}$), coronary atherosclerosis ($|\beta| > 0.07$, $P < 6.94 \times 10^{-10}$), and
24 peripheral artery diseases ($|\beta| > 0.21$, $P < 4.98 \times 10^{-5}$). Kidney diseases, especially nephrotic
25 syndrome, often lead to thrombotic and embolic complications, increasing the risk of
26 stroke, due to platelet over-activation and the use of diuretics and glucocorticoids that
27 can exacerbate hypercoagulability⁸⁰⁻⁸². For brain-related disorders, we observed causal
28 effects from liver volume to alcohol use disorder, as well as mental and behavioral
29 disorders due to alcohol and psychoactive substance use. In addition, percent liver fat
30 was causally linked with Alzheimer's disease, dementia, and psychiatric diseases. Prior
31 studies have reported that non-alcoholic fatty liver disease may contribute to
32 neurological conditions such as cognitive impairment and memory loss via pathways of

1 insulin resistance, inflammation, and excessive cytokine secretion⁸³⁻⁸⁶. In conclusion, we
2 found that brain-related disorders can lead to changes in abdominal organs, and that
3 these bidirectional relationships are observed in both neurodegenerative and psychiatric
4 disorders. Conversely, various abdominal organs were found to be causally linked to
5 heart-related diseases.

6

7 **Causal genetic links between skeleton DXA traits and clinical outcomes**

8 We first identified the causal effects of multiple organ diseases on DXA-derived skeleton
9 traits³. At the Bonferroni significance level ($P < 3.39 \times 10^{-5}$), we found compelling evidence
10 that multi-organ diseases impacted human skeleton health. The majority of these
11 diseases were heart-related diseases (6/12) and nervous system (4/12), with rheumatic
12 disease (1/12) and diseases of the genitourinary system (1/12) also having an impact (**Fig.**
13 **S23** and **Table S6**). Carpal tunnel syndrome ($|\beta| > 0.0007$, $P < 6.25 \times 10^{-8}$) and sleep apnoea
14 ($|\beta| > 0.001$, $P < 6.35 \times 10^{-8}$) were causally related to a higher average forearm length.
15 Carpal tunnel syndrome occurs when the median nerve, which extends from the forearm
16 to the palm of the hand, is compressed, impacting the wrist-to-forearm ratio^{87,88}. It has
17 been observed that oral appliance therapy⁸⁹, an effective treatment of sleep apnea, is
18 associated with skeletal changes⁹⁰. Moreover, disorders of the nerve, nerve root, and
19 plexus disorders were causally linked with higher average tibia length ($|\beta| > 0.001$, $P <$
20 2.78×10^{-5}), which aligns with the previous finding that a specific type of plexus disorder,
21 the lumbosacral plexus disorder, is associated with the lower leg⁹¹. Heart-related diseases
22 also had causal effects on several DXA traits. For example, coronary heart disease had a
23 negative causal effect on average tibia length ($|\beta| > 0.0002$, $P < 2.50 \times 10^{-5}$), and a positive
24 causal effect on hip width ($|\beta| > 0.0004$, $P < 1.68 \times 10^{-5}$). Additionally, gonarthrosis affected
25 the average tibia length ($|\beta| > 0.0005$, $P < 1.69 \times 10^{-5}$) (**Figs. 6A** and **S24**).

26

27 The skeletal system serves as the foundational support for the human body, and as such,
28 skeletal abnormalities could potentially contribute to the risk of multi-organ diseases. We
29 identified 17 causal pairs at the Bonferroni significance level ($P < 3.39 \times 10^{-5}$). Over half
30 (10/17) of these results were related to the heart, with the remainder pertaining to
31 rheumatic disease (3/17), diseases of the eye and adnexa (2/17), interstitial lung diseases
32 (1/17), and diseases of the genitourinary system (1/17) (**Fig. S23** and **Table S6**). Average

1 tibia length was causally linked to coxarthrosis ($|\beta| > 30.03$, $P < 3.11 \times 10^{-9}$), gonarthrosis
2 ($|\beta| > 19.39$, $P < 3.18 \times 10^{-7}$), and other rheumatological endpoints ($|\beta| > 13.12$, $P < 2.74 \times 10^{-5}$). There is evidence that leg length discrepancy could lead to issues with lower limb
3 biomechanics, such as gonarthrosis, coxarthrosis, and other lower limb symptoms^{92,93}.
4 Torso length was found to causally affect heart-related issues, such as coronary
5 angioplasty ($|\beta| > 38.85$, $P < 9.45 \times 10^{-5}$), coronary atherosclerosis ($|\beta| > 22.94$, $P < 1.22 \times 10^{-5}$),
6 hard cardiovascular diseases ($|\beta| > 18.12$, $P < 1.30 \times 10^{-5}$), and ischemic heart diseases
7 ($|\beta| > 30.99$, $P < 1.33 \times 10^{-5}$). Previous studies examining the relationship between skeletal
8 length and heart diseases have primarily focused on leg length or overall body height,
9 generally reporting negative associations^{94,95}. Consistent with these associations, we
10 found that a long torso can lead to a higher risk of heart disease. We also observed that
11 a higher average tibia length is causally linked to a lower risk of hypertension ($|\beta| > 6.46$,
12 $P < 1.27 \times 10^{-7}$), which is in line with previous findings⁹⁶ (**Figs. 6B** and **S25**). In conclusion,
13 we found that rheumatoid endpoints (such as gonarthrosis) and diseases of the nervous
14 system (such as nerve, nerve root, and plexus disorders) had a significant impact on bone
15 health. Conversely, skeletal traits, like torso length, demonstrated a causal link with heart
16 diseases.
17

18

19 **Discussion**

20 Observational studies have identified numerous links between various imaging-derived
21 phenotypes and clinical outcomes. However, these associations are often influenced by
22 residual confounding, complicating the accurate inference of causal effect sizes⁹⁷. MR
23 allows for the inference of causal relationships between exposure and outcome variables.
24 MR leverages the natural and random assortment of genetic variants during meiosis,
25 making these variants ideal instrumental variables for discerning causal effects. In the
26 present study, we evaluated the causal relationship between 402 multi-organ imaging
27 biomarkers and 88 clinical outcomes through bidirectional MR. To circumvent the issue
28 of sample overlap⁹⁸, which can bias the causal effect and has been overlooked in many
29 current MR-based studies, we utilized a two-sample MR design and sourced our imaging
30 and clinical data from different large-scale cohorts. The interconnected nature of our
31 organ systems means that diseases often affect more than one part of the human body.
32 The brain and heart are particularly critical, with the brain controlling a variety of

1 functions, including reactions, emotions, vision, memory, and cognition^{99,100}, while the
2 heart acts as the body's engine, pumping oxygen and nutrient-rich blood to other organs.
3 Dysfunctions in various organs can potentially have detrimental effects on the brain and
4 heart, and vice versa. Besides connections to the brain and heart, we also uncovered
5 many other causal relationships across different organs. A visualization of the interactions
6 across different organ systems can be found in Figure 1B. We will delve into these specific
7 findings in more detail below.

8

9 *Intra-brain causal connections.*

10 Alternations in brain structure and function were found to be closely linked with brain
11 disorders, with some of these relationships appearing to be bidirectional. We consistently
12 identified causal connections between brain imaging biomarkers and a variety of
13 psychiatric disorders or neurological diseases, such as Alzheimer's disease, dementia,
14 mood disorder, and sleep apnea. For example, Alzheimer's disease and dementia
15 exhibited bidirectional causal relationships with fMRI traits and DTI parameters. Prior
16 studies have consistently reported that resting fMRI connectivity patterns are disrupted
17 in patients with Alzheimer's disease^{101,102}, particularly in brain regions involved in
18 memory and cognitive function^{103,104}.

19

20 *Brain-heart causal connections.*

21 Despite the increasing number of association studies investigating the brain-heart
22 interaction^{39,105}, causal genetic links within these systems remain largely uncharted. In
23 our research, we identified causal connections from several heart-related diseases such
24 as hypertension, hypertensive diseases, heart failure, and peripheral artery disease, to
25 DTI parameters in white matter tracts. These tracts include the SCR, ALIC, BCC, GCC, the
26 splenium of corpus callosum, and the retrolenticular part of the internal capsule (RLIC).
27 Additionally, these diseases were also linked to regional brain volumes, such as grey
28 matter and left amygdala. Hypertension can lead to damage in the brain's blood vessels¹⁰⁶,
29 which may, in turn, cause a reduction in the volume of grey matter in certain brain
30 regions¹⁰⁷. This could potentially result in cognitive impairment and an increased risk of
31 developing dementia. Hence, effective management of hypertension through lifestyle
32 adjustments and medication could help mitigate these adverse effects on the brain.

1 Conversely, we found that alterations in brain structure, such as deformations in the left
2 ventral DC and left basal forebrain, contributed to heart-related diseases like
3 hypertension. Changes in the left superior temporal region were also linked to heart
4 failure. These associations could be attributed to the brain's essential function in
5 regulating blood pressure through a complex network involving multiple regions and
6 pathways^{108,109}.

7

8 *Bidirectional connections between the brain and abdominal organs.*

9 Brain abnormalities were found to influence multiple abdominal organs as well as the
10 skeletal system. For example, Alzheimer's disease and dementia were observed causally
11 influencing percent liver fat. Additionally, neurological diseases (defined by FinnGen²⁷)
12 exhibited a positive causal effect on lung volume. This could be attributed to the fact that
13 neurological diseases, such as multiple sclerosis, Parkinson's disease, amyotrophic lateral
14 sclerosis, and Huntington's disease, can induce respiratory muscle weakness^{110,111}. This
15 weakness could subsequently influence lung volume and functionality. We also found
16 that sleep apnoea may cause an increase in spleen and kidney volume. This could be due
17 to the heightened workload on the spleen to filter blood and remove damaged red blood
18 cells. Additionally, the low oxygen levels associated with sleep apnea can lead to an
19 increase in the number of red blood cells in the body, which could contribute to
20 splenomegaly and a change in kidney volume. Furthermore, sleep apnea was observed to
21 be causally associated with an increase in pancreas iron content. This could potentially
22 be due to the decreased oxygen levels that accompany sleep apnea, resulting in an
23 increase in iron absorption within the body. Excess iron in the pancreas can lead to
24 oxidative stress and inflammation^{112,113}, which can contribute to the development of
25 pancreatic damage and dysfunction¹¹⁴⁻¹¹⁶. In addition to the previously mentioned
26 neurological diseases, our study revealed that mental and behavioral disorders related to
27 alcohol use can cause an increase in liver fat percentage. It is well documented that
28 individual suffering from alcohol use disorder are more prone to develop alcoholic fatty
29 liver disease¹¹⁷. Beyond brain-related diseases, alternations in brain structure could also
30 contribute to a heightened risk of diseases in other organs. For example, changes in the
31 right postcentral gyrus were causally linked to COPD. Some studies suggest that chronic

1 stress and anxiety, which are associated with changes in brain structure, may contribute
2 to the development or exacerbation of respiratory conditions such as COPD^{118,119}.
3 Conversely, brain imaging biomarkers or disorders were causally affected by various
4 diseases of other organs or systems. A high percentage of liver fat led to a reduced risk of
5 Alzheimer's disease and dementia. Past studies^{120,121} have reported associations between
6 the two and our results aligned with the most recent study¹²². Further research is
7 necessary to elucidate the underlying pathophysiological mechanism. Brain imaging
8 biomarkers were impacted by diseases across multiple organs, although some may affect
9 the brain indirectly, perhaps via the mediating effects of anxiety and depression. For
10 instance, diseases of the genitourinary system (such as ovarian cyst and menorrhagia)
11 causally influenced brain structural features. Ovarian cysts can cause hormonal
12 imbalances due to the hormones they produce¹²³. These hormonal shifts can prompt a
13 variety of symptoms, including mood swings, anxiety, and depression¹²⁴, which can
14 impact brain function and emotional regulation. Diseases of the eye and adnexa
15 (conjunctivitis) demonstrated genetic causal effects on functional connectivity traits.
16 Conjunctivitis can result from viral or bacterial infections, potentially leading to
17 systemic inflammation in the body¹²⁵. Such systemic inflammation has been linked to
18 changes in brain function and structure, and may influence brain fMRI traits^{126,127}.
19
20 Moreover, asthma influenced regional brain volumes. A common mechanism through
21 which asthma affects the brain is via the emotional and psychological stress associated
22 with managing a chronic illness. Anxiety, stress, and depression, which are often
23 experienced by individuals with asthma, can result in alterations to brain structure. Prior
24 studies have demonstrated that individuals with asthma may have diminished cognitive
25 function, including impaired memory and attention, as well as changes in brain activity
26 patterns during cognitive tasks^{128,129}. Notably, autoimmune diseases (as defined by
27 FinnGen²⁷) impacted brain imaging biomarkers, such as DTI parameters of the RLIC and
28 SCR. Multiple sclerosis, an autoimmune disease affecting the central nervous system, can
29 cause damage to the myelin sheath that surrounds axons and can occur in various brain
30 regions^{130,131}, including the internal capsule. This damage can disrupt neural connections
31 passing through the anterior limb, leading to symptoms like weakness, spasticity, and
32 difficulty with balance and coordination. In rare autoimmune diseases, such as

1 neuromyelitis optica¹³² and autoimmune encephalitis, inflammation, and damage can
2 occur in the brain. The resulting neurological symptoms can vary based on the severity
3 and location of the damage^{133,134}. Additionally, autoimmune diseases causing systemic
4 inflammation, such as rheumatoid arthritis and lupus, could potentially affect the brain¹³⁵
5 and white matter tracts^{136,137}. Chronic inflammation can lead to changes in the
6 microstructure of white matter tracts, resulting in alterations in neural connectivity and
7 function^{138,139}.

8

9 *Intra-heart causal connections.*

10 Bidirectional causal relationships were observed between heart-related diseases and
11 CMR traits. Hypertension and hypertensive diseases were found to causally influence
12 several CMR traits across different heart chambers and aorta regions. Conversely,
13 alternations in CMR traits were suggested to potentially result in heart diseases. These
14 findings corroborate with existing clinical evidence. For example, hypertension can lead
15 to enlargement of the LA, a condition known as left atrial hypertrophy^{140,141}. This
16 enlargement can result in various complications, including atrial fibrillation, heart failure,
17 and stroke¹⁴². In the case of atrial fibrillation, the electrical signals that regulate the
18 heartbeat become erratic, causing an irregular and often repaid heartbeat. Over time, this
19 persistent irregularity can further enlarge and weaken¹⁴³.

20

21 *Bidirectional connections between the heart and abdominal organs.*

22 Heart diseases were found to be causally linked with various multi-organ imaging
23 biomarkers. For instance, heart failure was observed to result in an increase in spleen
24 volume. When the heart is unable to pump blood effectively, it can cause a rise in pressure
25 from the veins leading to the spleen. This increased pressure can cause the spleen to
26 enlarge, a condition known as splenomegaly¹⁴⁴. In addition, the congestion of blood in
27 the liver, which can occur with heart failure, can also contribute to splenomegaly.
28 Conversely, a larger spleen volume can lead to heart failure. An enlarged spleen can
29 intensify the workload on the heart, leading to further deterioration of heart failure
30 symptoms.

31

1 The pancreas was also identified to have a causal effect on the heart. For example, excess
2 pancreas fat was associated with a higher risk of developing deep vein thrombosis of
3 lower extremities and pulmonary embolism. Pancreatic steatosis, a condition where fat
4 accumulates in the pancreas, is linked with several metabolic abnormalities, including
5 insulin resistance and inflammation, which can contribute to the development of
6 cardiovascular diseases^{145,146}. The proinflammatory and procoagulant effects of excess
7 pancreatic fat could potentially contribute to an increased risk of deep vein thrombosis.
8 The heart and lungs are intricately connected, working in conjunction as part of the
9 cardiovascular system. The lungs are responsible for inhaling oxygen from the air and
10 transferring it into the bloodstream, while the heart pumps the oxygen-rich blood
11 throughout the body, nourishing cells and tissues. We identified strong evidence of causal
12 links between COPD and CMR traits of DAo. A hallmark of emphysema is the degradation
13 of elastic fibers via proteolysis¹⁴⁷, which can potentially cause enlargement of the thoracic
14 aorta.

15

16 The spleen, as the body's largest immune organ, has been found to be closely related to
17 diseases marked as autoimmune origin. Our study uncovered robust evidence of a genetic
18 causal relationship between spleen volume and autoimmune diseases, as defined by
19 FinnGen²⁷, including conditions like rheumatoid arthritis, systemic lupus erythematosus,
20 and systemic sclerosis. There are documented instances where autoimmune diseases
21 affect the spleen. For instance, conditions such as lupus or rheumatoid arthritis can result
22 in splenomegaly, a condition that is often triggered by inflammation or the accumulation
23 of abnormal immune cells within the spleen^{148,149}.

24

25 *Skeleton DXA traits.*

26 We also found genetic causal connections between DXA-derived skeleton traits and
27 multiple organ diseases. Skeleton traits were shown to be causally affected by diseases
28 of the nervous system, rheumatic disease, and disorders of the nerve, nerve root and
29 plexus. Heart diseases can also influence the skeletal system by influencing bone health.
30 It has been observed that individuals with heart disease, especially those suffering from
31 heart failure, have an increased risk of osteoporosis and bone fractures^{149,150}. This can be
32 attributed to various factors. For example, some medications used to treat heart diseases,

1 such as diuretics and steroids, can increase the risk of osteoporosis¹⁵¹. Additionally,
2 individuals with heart disease may experience reduced mobility and physical activity,
3 leading to decreased bone density and strength¹⁵². Conversely, skeleton problems could
4 contribute to numerous organ diseases, with heart conditions being the most prevalent
5 in our analysis. A longer torso may lead to an increased risk of coronary heart disease. We
6 also observed that a higher average tibia length was causally linked to a lower risk of
7 hypertension, a finding that aligns with previous clinical observations⁹⁶.

8 9 Limitations and conclusions.

10 Our study does come with several limitations. Firstly, our collection of GWAS summary
11 statistics was sourced from publicly available databases. Thus, we could not evaluate the
12 impact of unobserved confounders, such as population stratification, on our results.
13 Secondly, a common limitation that most existing MR methods share is that they require
14 several model assumptions. This may result in model misspecifications and issues related
15 to data heterogeneity when integrating data from different data resources¹⁵³. We have
16 systematically applied quality control measures and conducted sensitivity analyses in our
17 study. Future research implementing more advanced MR methods may relax some of
18 these model assumptions^{154,155}. Furthermore, MR studies are designed to examine the
19 effects of lifetime exposure factors on outcomes, not interventions within a specified
20 period. As a result, our findings may be interpreted differently than the rigorous results
21 obtained from randomized controlled trials. Therefore, any clinical interventions based
22 on these MR findings should be pursued.

23
24 In conclusion, we used two-sample bidirectional MR analyses to comprehensively explore
25 the multi-organ causal connections between 88 clinical outcomes and 402 image-derived
26 phenotypes of various organ systems. Our results revealed robust genetic evidence
27 supporting causal connections within and across multiple organs. This will be
28 instrumental in unraveling complex pathogenic mechanisms and will contribute to the
29 early prediction and prevention of multi-organ diseases from a whole-body perspective.

30 31 32 **METHODS**

1 Methods are available in the **Methods** section.

2 *Note: One supplementary pdf file and one supplementary table zip file are available.*

3

4 **ACKNOWLEDGEMENTS**

5 The study has been partially supported by funding from the Wharton Dean's Research
6 Fund and Analytics at Wharton, as well as start-up funds from Purdue Statistics
7 Department. This research has been conducted using summary-level data from the UK
8 Biobank study and the FinnGen research project. We would like to thank the individuals
9 who represented themselves in the UK Biobank and FinnGen studies for their
10 participation and the research teams for their efforts in collecting, processing, and
11 disseminating these datasets. We would like to thank the research computing groups at
12 the University of North Carolina at Chapel Hill, Purdue University, and the Wharton School
13 of the University of Pennsylvania for providing computational resources and support that
14 have contributed to these research results.

15

16 **AUTHOR CONTRIBUTIONS**

17 J.S. and B.Z. designed the study. J.S., R.Z., C.C., B.L., Z. F., X.Y., Y.Y, X.W., and Y.L. analyzed
18 the data. B.X., T.L., and H.Z. provided feedback on the results. J.S. and B.Z. wrote the
19 manuscript with feedback from all authors.

20

21 **CORRESPONDENCE AND REQUESTS FOR MATERIALS** should be addressed to H.Z. and B.Z.

22

23 **COMPETING FINANCIAL INTERESTS**

24 The authors declare no competing financial interests.

25

26 **REFERENCES**

- 27 1. Buckner, R.L., *et al.* Molecular, structural, and functional characterization of
28 Alzheimer's disease: evidence for a relationship between default activity,
29 amyloid, and memory. *Journal of neuroscience* **25**, 7709-7717 (2005).
- 30 2. Pennell, D.J., *et al.* Clinical indications for cardiovascular magnetic resonance
31 (CMR): Consensus Panel report. *European heart journal* **25**, 1940-1965 (2004).

- 1 3. Kun, E., *et al.* The genetic architecture of the human skeletal form. *bioRxiv*,
2 2023.2001. 2003.521284 (2023).
- 3 4. Petersen, S.E., *et al.* UK Biobank’s cardiovascular magnetic resonance protocol.
4 *Journal of cardiovascular magnetic resonance* **18**, 1-7 (2015).
- 5 5. Littlejohns, T.J., Sudlow, C., Allen, N.E. & Collins, R. UK Biobank: opportunities for
6 cardiovascular research. *European heart journal* **40**, 1158-1166 (2019).
- 7 6. Miller, K.L., *et al.* Multimodal population brain imaging in the UK Biobank
8 prospective epidemiological study. *Nature Neuroscience* **19**, 1523-1536 (2016).
- 9 7. Thompson, P.M., *et al.* ENIGMA and global neuroscience: A decade of large-scale
10 studies of the brain in health and disease across more than 40 countries.
11 *Translational psychiatry* **10**, 1-28 (2020).
- 12 8. Liu, Y., *et al.* Genetic architecture of 11 organ traits derived from abdominal MRI
13 using deep learning. *Elife* **10**, e65554 (2021).
- 14 9. Smith, S.M. & Nichols, T.E. Statistical challenges in “big data” human
15 neuroimaging. *Neuron* **97**, 263-268 (2018).
- 16 10. Tian, Y.E., *et al.* Heterogeneous aging across multiple organ systems and
17 prediction of chronic disease and mortality. *Nature Medicine*, 1-11 (2023).
- 18 11. Taschler, B., Smith, S.M. & Nichols, T.E. Causal inference on neuroimaging data
19 with Mendelian randomisation. *NeuroImage*, 119385 (2022).
- 20 12. Sanderson, E., *et al.* Mendelian randomization. *Nature Reviews Methods Primers*
21 **2**, 1-21 (2022).
- 22 13. Pingault, J.-B., *et al.* Using genetic data to strengthen causal inference in
23 observational research. *Nature Reviews Genetics* **19**, 566-580 (2018).
- 24 14. Aung, N., *et al.* Genome-wide analysis of left ventricular image-derived
25 phenotypes identifies fourteen loci associated with cardiac morphogenesis and
26 heart failure development. *Circulation* **140**, 1318-1330 (2019).
- 27 15. Córdova-Palomera, A., *et al.* Cardiac Imaging of Aortic Valve Area From 34 287
28 UK Biobank Participants Reveals Novel Genetic Associations and Shared Genetic
29 Comorbidity With Multiple Disease Phenotypes. *Circulation: Genomic and*
30 *Precision Medicine* **13**, e003014 (2020).
- 31 16. Meyer, H.V., *et al.* Genetic and functional insights into the fractal structure of the
32 heart. *Nature* **584**, 589-594 (2020).

- 1 17. Pirruccello, J.P., *et al.* Analysis of cardiac magnetic resonance imaging in 36,000
2 individuals yields genetic insights into dilated cardiomyopathy. *Nature*
3 *communications* **11**, 1-10 (2020).
- 4 18. Pirruccello, J.P., *et al.* Genetic Analysis of Right Heart Structure and Function in
5 40,000 People. *bioRxiv* (2021).
- 6 19. Thanaj, M., *et al.* Genetic and environmental determinants of diastolic heart
7 function. *medRxiv* (2021).
- 8 20. Elliott, L.T., *et al.* Genome-wide association studies of brain imaging phenotypes
9 in UK Biobank. *Nature* **562**, 210-216 (2018).
- 10 21. Zhao, B., *et al.* Genome-wide association analysis of 19,629 individuals identifies
11 variants influencing regional brain volumes and refines their genetic co-
12 architecture with cognitive and mental health traits. *Nature genetics* **51**, 1637-
13 1644 (2019).
- 14 22. Smith, S.M., *et al.* An expanded set of genome-wide association studies of brain
15 imaging phenotypes in UK Biobank. *Nature neuroscience* **24**, 737-745 (2021).
- 16 23. Zhao, B., *et al.* Common genetic variation influencing human white matter
17 microstructure. *Science* **372**, eabf3736 (2021).
- 18 24. Grasby, K.L., *et al.* The genetic architecture of the human cerebral cortex. *Science*
19 **367**, eaay6690 (2020).
- 20 25. Zhao, B., *et al.* Genetic influences on the intrinsic and extrinsic functional
21 organizations of the cerebral cortex. *medRxiv*, 2021.2007. 2027.21261187
22 (2021).
- 23 26. Watanabe, K., *et al.* A global overview of pleiotropy and genetic architecture in
24 complex traits. *Nature genetics* **51**, 1339-1348 (2019).
- 25 27. Kurki, M.I., *et al.* FinnGen: Unique genetic insights from combining isolated
26 population and national health register data. *medRxiv* (2022).
- 27 28. Flynn, B.I., *et al.* Deep learning based phenotyping of medical images improves
28 power for gene discovery of complex disease. *medRxiv*, 2023.2003.
29 2007.23286909 (2023).
- 30 29. Kun, E., *et al.* The genetic architecture of the human skeletal form. *bioRxiv*
31 (2023).

- 1 30. Guo, J., *et al.* Mendelian randomization analyses support causal relationships
2 between brain imaging-derived phenotypes and risk of psychiatric disorders.
3 *Nature Neuroscience* **25**, 1519-1527 (2022).
- 4 31. Chen, X., *et al.* Kidney damage causally affects the brain cortical structure: a
5 Mendelian randomization study. *EBioMedicine* **72**, 103592 (2021).
- 6 32. Williams, J.A., *et al.* Inflammation and brain structure in schizophrenia and other
7 neuropsychiatric disorders: a Mendelian randomization study. *JAMA psychiatry*
8 **79**, 498-507 (2022).
- 9 33. Topiwala, A., *et al.* Associations between moderate alcohol consumption, brain
10 iron, and cognition in UK Biobank participants: observational and mendelian
11 randomization analyses. *PLoS medicine* **19**, e1004039 (2022).
- 12 34. Holmes, M.V., *et al.* Mendelian randomization of blood lipids for coronary heart
13 disease. *European heart journal* **36**, 539-550 (2015).
- 14 35. Lamina, C. & Kronenberg, F. Estimation of the required lipoprotein (a)-lowering
15 therapeutic effect size for reduction in coronary heart disease outcomes: a
16 Mendelian randomization analysis. *JAMA cardiology* **4**, 575-579 (2019).
- 17 36. Sudlow, C., *et al.* UK biobank: an open access resource for identifying the causes
18 of a wide range of complex diseases of middle and old age. *PLoS medicine* **12**,
19 e1001779 (2015).
- 20 37. Bijsterbosch, J., *et al.* Investigations into within-and between-subject resting-
21 state amplitude variations. *Neuroimage* **159**, 57-69 (2017).
- 22 38. Bai, W., *et al.* A population-based phenome-wide association study of cardiac
23 and aortic structure and function. *Nature Medicine* **26**, 1654-1662 (2020).
- 24 39. Zhao, B., *et al.* Heart-brain connections: phenotypic and genetic insights from
25 magnetic resonance images. *Science*, just-accepted (2023).
- 26 40. Bowden, J., *et al.* A framework for the investigation of pleiotropy in two-sample
27 summary data Mendelian randomization. *Statistics in medicine* **36**, 1783-1802
28 (2017).
- 29 41. Burgess, S., Butterworth, A. & Thompson, S.G. Mendelian randomization analysis
30 with multiple genetic variants using summarized data. *Genetic epidemiology* **37**,
31 658-665 (2013).

- 1 42. Bowden, J., *et al.* Improving the accuracy of two-sample summary-data
2 Mendelian randomization: moving beyond the NOME assumption. *Int J*
3 *Epidemiol* **48**, 728-742 (2019).
- 4 43. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
5 instruments: effect estimation and bias detection through Egger regression.
6 *International journal of epidemiology* **44**, 512-525 (2015).
- 7 44. Hartwig, F.P., Davey Smith, G. & Bowden, J. Robust inference in summary data
8 Mendelian randomization via the zero modal pleiotropy assumption.
9 *International journal of epidemiology* **46**, 1985-1998 (2017).
- 10 45. Bowden, J., Davey Smith, G., Haycock, P.C. & Burgess, S. Consistent estimation in
11 Mendelian randomization with some invalid instruments using a weighted
12 median estimator. *Genetic epidemiology* **40**, 304-314 (2016).
- 13 46. Ye, T., Shao, J. & Kang, H. Debiased inverse-variance weighted estimator in two-
14 sample summary-data Mendelian randomization. *The Annals of statistics* **49**,
15 2079-2100 (2021).
- 16 47. Zhao, Q., Wang, J., Hemani, G., Bowden, J. & Small, D.S. Statistical inference in
17 two-sample summary-data Mendelian randomization using robust adjusted
18 profile score. *The Annals of Statistics* **48**, 1742-1769 (2020).
- 19 48. Wang, J., *et al.* Causal inference for heritable phenotypic risk factors using
20 heterogeneous genetic instruments. *PLoS genetics* **17**, e1009575 (2021).
- 21 49. Oishi, K., Mielke, M.M., Albert, M., Lyketsos, C.G. & Mori, S. DTI analyses and
22 clinical applications in Alzheimer's disease. *J Alzheimers Dis* **26 Suppl 3**, 287-296
23 (2011).
- 24 50. Yin, R.-H., *et al.* Multimodal voxel-based meta-analysis of white matter
25 abnormalities in Alzheimer's disease. *Journal of Alzheimer's Disease* **47**, 495-507
26 (2015).
- 27 51. Li, R., *et al.* Attention-related networks in Alzheimer's disease: A resting
28 functional MRI study. *Human brain mapping* **33**, 1076-1088 (2012).
- 29 52. Stratos, C., Stefanadis, C., Kallikazaros, I., Boudoulas, H. & Toutouzas, P.
30 Ascending aorta distensibility abnormalities in hypertensive patients and
31 response to nifedipine administration. *The American journal of medicine* **93**, 505-
32 512 (1992).

- 1 53. Asmar, R., *et al.* Aortic distensibility in normotensive, untreated and treated
2 hypertensive patients. *Blood pressure* **4**, 48-54 (1995).
- 3 54. Nabati, M., Namazi, S.S., Yazdani, J. & Sharif Nia, H. Relation between aortic
4 stiffness index and distensibility with age in hypertensive patients. *International*
5 *journal of general medicine*, 297-303 (2020).
- 6 55. Lembo, M., *et al.* Advanced imaging tools for evaluating cardiac morphological
7 and functional impairment in hypertensive disease. *Journal of Hypertension* **40**,
8 4-14 (2022).
- 9 56. Di Palo, K.E. & Barone, N.J. Hypertension and heart failure: prevention, targets,
10 and treatment. *Heart failure clinics* **16**, 99-106 (2020).
- 11 57. Gopinathannair, R., *et al.* Managing atrial fibrillation in patients with heart failure
12 and reduced ejection fraction: a scientific statement from the American Heart
13 Association. *Circulation: Arrhythmia and Electrophysiology* **14**, e000078 (2021).
- 14 58. Packer, M. Do most patients with obesity or type 2 diabetes, and atrial
15 fibrillation, also have undiagnosed heart failure? A critical conceptual framework
16 for understanding mechanisms and improving diagnosis and treatment.
17 *European journal of heart failure* **22**, 214-227 (2020).
- 18 59. Fujikura, K., *et al.* Aortic enlargement in chronic obstructive pulmonary disease
19 (COPD) and emphysema: The Multi-Ethnic Study of Atherosclerosis (MESA) COPD
20 study. *Int J Cardiol* **331**, 214-220 (2021).
- 21 60. Maclay, J.D., *et al.* Systemic elastin degradation in chronic obstructive pulmonary
22 disease. *Thorax* **67**, 606-612 (2012).
- 23 61. Berman, M.N., Tupper, C. & Bhardwaj, A. Physiology, Left Ventricular Function.
24 (2019).
- 25 62. Kim, D.-Y. & Camilleri, M. Serotonin: a mediator of the brain–gut connection.
26 *Official journal of the American College of Gastroenterology| ACG* **95**, 2698-2709
27 (2000).
- 28 63. Jones, M., Dille, J., Drossman, D. & Crowell, M. Brain–gut connections in
29 functional GI disorders: anatomic and physiologic relationships.
30 *Neurogastroenterology & Motility* **18**, 91-103 (2006).
- 31 64. Keefer, L., *et al.* A Rome working team report on brain-gut behavior therapies for
32 disorders of gut-brain interaction. *Gastroenterology* **162**, 300-315 (2022).

- 1 65. Xie, Z., Tong, S., Chu, X., Feng, T. & Geng, M. Chronic kidney disease and
2 cognitive impairment: The kidney-brain axis. *Kidney Diseases* **8**, 275-285 (2022).
- 3 66. de Donato, A., Buonincontri, V., Borriello, G., Martinelli, G. & Mone, P. The
4 dopamine system: insights between kidney and brain. *Kidney and Blood Pressure*
5 *Research* **47**, 493-505 (2022).
- 6 67. McCracken, C., *et al.* Multi-organ imaging demonstrates the heart-brain-liver axis
7 in UK Biobank participants. *Nature Communications* **13**, 7839 (2022).
- 8 68. Voulgaris, A., Marrone, O., Bonsignore, M.R. & Steiropoulos, P. Chronic kidney
9 disease in patients with obstructive sleep apnea. A narrative review. *Sleep*
10 *Medicine Reviews* **47**, 74-89 (2019).
- 11 69. Sim, J.J., Rasgon, S.A. & Derosé, S.F. Managing sleep apnoea in kidney diseases.
12 *Nephrology* **15**, 146-152 (2010).
- 13 70. O'Reilly, R.A. Splenomegaly in 2,505 patients in a large university medical center
14 from 1913 to 1995. 1913 to 1962: 2,056 patients. *Western journal of medicine*
15 **169**, 78 (1998).
- 16 71. Vinchi, F., *et al.* Atherosclerosis is aggravated by iron overload and ameliorated
17 by dietary and pharmacological iron restriction. *European heart journal* **41**, 2681-
18 2695 (2020).
- 19 72. Kempf, T. & Wollert, K.C. Iron and atherosclerosis: too much of a good thing can
20 be bad. *European Heart Journal* (2020).
- 21 73. Balint, G.P. & Balint, P.V. Felty's syndrome. *Best practice & research clinical*
22 *rheumatology* **18**, 631-645 (2004).
- 23 74. Blendis, L., Ansell, I., Jones, K.L., Hamilton, E. & Williams, R. Liver in Felty's
24 syndrome. *Br Med J* **1**, 131-135 (1970).
- 25 75. Kataria, Y.P. & Whitcomb, M.E. Splenomegaly in sarcoidosis. *Archives of Internal*
26 *Medicine* **140**, 35-37 (1980).
- 27 76. Candia, L., Marquez, J. & Espinoza, L.R. Autoimmune hepatitis and pregnancy: a
28 rheumatologist's dilemma. in *Seminars in arthritis and rheumatism*, Vol. 35 49-56
29 (Elsevier, 2005).
- 30 77. Wang, Z., *et al.* Iron drives T helper cell pathogenicity by promoting RNA-binding
31 protein PCBP1-mediated proinflammatory cytokine production. *Immunity* **49**, 80-
32 92. e87 (2018).

- 1 78. Erie, J.C., *et al.* Heavy metal concentrations in human eyes. *American journal of*
2 *ophthalmology* **139**, 888-893 (2005).
- 3 79. Honka, H., *et al.* The effects of bariatric surgery on pancreatic lipid metabolism
4 and blood flow. *The Journal of Clinical Endocrinology & Metabolism* **100**, 2015-
5 2023 (2015).
- 6 80. Huang, J.-A., Lin, C.-H., Chang, Y.-T., Lee, C.-T. & Wu, M.-J. Nephrotic syndrome is
7 associated with increased risk of ischemic stroke. *Journal of Stroke and*
8 *Cerebrovascular Diseases* **28**, 104322 (2019).
- 9 81. Gigante, A., *et al.* Nephrotic syndrome and stroke. *International Journal of*
10 *Immunopathology and Pharmacology* **26**, 769-772 (2013).
- 11 82. Roy, C., *et al.* Ischemic stroke of possible embolic etiology associated with
12 nephrotic syndrome. *Kidney International Reports* **2**, 988-994 (2017).
- 13 83. Cheon, S.Y. & Song, J. Novel insights into non-alcoholic fatty liver disease and
14 dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular
15 impairment, and inflammation. *Cell & Bioscience* **12**, 1-14 (2022).
- 16 84. Rodrigo, R., *et al.* Hyperammonemia induces neuroinflammation that
17 contributes to cognitive impairment in rats with hepatic encephalopathy.
18 *Gastroenterology* **139**, 675-684 (2010).
- 19 85. Rose, C.F., *et al.* Hepatic encephalopathy: Novel insights into classification,
20 pathophysiology and therapy. *Journal of hepatology* **73**, 1526-1547 (2020).
- 21 86. Kong, S.H., Park, Y.J., Lee, J.-Y., Cho, N.H. & Moon, M.K. Insulin resistance is
22 associated with cognitive decline among older Koreans with normal baseline
23 cognitive function: a prospective community-based cohort study. *Scientific*
24 *reports* **8**, 650 (2018).
- 25 87. Hobson-Webb, L.D., Massey, J.M., Juel, V.C. & Sanders, D.B. The
26 ultrasonographic wrist-to-forearm median nerve area ratio in carpal tunnel
27 syndrome. *Clinical neurophysiology* **119**, 1353-1357 (2008).
- 28 88. Paluch, Ł., Pietruski, P., Walecki, J. & Noszczyk, B.H. Wrist to forearm ratio as a
29 median nerve shear wave elastography test in carpal tunnel syndrome diagnosis.
30 *Journal of Plastic, Reconstructive & Aesthetic Surgery* **71**, 1146-1152 (2018).

- 1 89. Gotsopoulos, H., Chen, C., Qian, J. & Cistulli, P.A. Oral appliance therapy
2 improves symptoms in obstructive sleep apnea: a randomized, controlled trial.
3 *American journal of respiratory and critical care medicine* **166**, 743-748 (2002).
- 4 90. Araie, T., Okuno, K., Minagi, H.O. & Sakai, T. Dental and skeletal changes
5 associated with long-term oral appliance use for obstructive sleep apnea: a
6 systematic review and meta-analysis. *Sleep Medicine Reviews* **41**, 161-172
7 (2018).
- 8 91. Sander, J.E. & Sharp, F.R. Lumbosacral plexus neuritis. *Neurology* **31**, 470-473
9 (1981).
- 10 92. Khamis, S. & Carmeli, E. A new concept for measuring leg length discrepancy.
11 *Journal of orthopaedics* **14**, 276-280 (2017).
- 12 93. Raczkowski, J.W., Daniszewska, B. & Zolynski, K. Functional scoliosis caused by
13 leg length discrepancy. *Archives of Medical Science* **6**, 393-398 (2010).
- 14 94. Nelson, C.P., *et al.* Genetically determined height and coronary artery disease.
15 *New England Journal of Medicine* **372**, 1608-1618 (2015).
- 16 95. Schmidt, M., Bøtker, H.E., Pedersen, L. & Sørensen, H.T. Adult height and risk of
17 ischemic heart disease, atrial fibrillation, stroke, venous thromboembolism, and
18 premature death: a population based 36-year follow-up study. *European journal*
19 *of epidemiology* **29**, 111-118 (2014).
- 20 96. Yin, F., Spurgeon, H.A., Rakusan, K., Weisfeldt, M.L. & Lakatta, E.G. Use of tibial
21 length to quantify cardiac hypertrophy: application in the aging rat. *American*
22 *Journal of Physiology-Heart and Circulatory Physiology* **243**, H941-H947 (1982).
- 23 97. Walker, V.M., Zheng, J., Gaunt, T.R. & Smith, G.D. Phenotypic Causal Inference
24 Using Genome-Wide Association Study Data: Mendelian Randomization and
25 Beyond. *Annu Rev Biomed Data Sci* **5**, 1-17 (2022).
- 26 98. Burgess, S., Davies, N.M. & Thompson, S.G. Bias due to participant overlap in
27 two-sample Mendelian randomization. *Genetic epidemiology* **40**, 597-608 (2016).
- 28 99. Berridge, K.C. & Kringelbach, M.L. Pleasure systems in the brain. *Neuron* **86**, 646-
29 664 (2015).
- 30 100. Bressler, S.L. & Menon, V. Large-scale brain networks in cognition: emerging
31 methods and principles. *Trends Cogn Sci* **14**, 277-290 (2010).

- 1 101. Wang, K., *et al.* Altered functional connectivity in early Alzheimer's disease: A
2 resting-state fMRI study. *Human brain mapping* **28**, 967-978 (2007).
- 3 102. Sorg, C., *et al.* Selective changes of resting-state networks in individuals at risk
4 for Alzheimer's disease. *Proceedings of the National Academy of Sciences* **104**,
5 18760-18765 (2007).
- 6 103. Ranasinghe, K.G., *et al.* Regional functional connectivity predicts distinct
7 cognitive impairments in Alzheimer's disease spectrum. *NeuroImage: Clinical* **5**,
8 385-395 (2014).
- 9 104. Pini, L., *et al.* A low-dimensional cognitive-network space in Alzheimer's disease
10 and frontotemporal dementia. *Alzheimer's Research & Therapy* **14**, 199 (2022).
- 11 105. Liu, W., *et al.* Brain–heart communication in health and diseases. *Brain Research*
12 *Bulletin* (2022).
- 13 106. Walker, K.A., Power, M.C. & Gottesman, R.F. Defining the relationship between
14 hypertension, cognitive decline, and dementia: a review. *Current hypertension*
15 *reports* **19**, 1-16 (2017).
- 16 107. Zhang, H., *et al.* Reduced regional gray matter volume in patients with chronic
17 obstructive pulmonary disease: a voxel-based morphometry study. *American*
18 *Journal of Neuroradiology* **34**, 334-339 (2013).
- 19 108. do Carmo, J.M., *et al.* Role of the brain melanocortins in blood pressure
20 regulation. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* **1863**,
21 2508-2514 (2017).
- 22 109. Goriely, A., *et al.* Mechanics of the brain: perspectives, challenges, and
23 opportunities. *Biomechanics and modeling in mechanobiology* **14**, 931-965
24 (2015).
- 25 110. Polkey, M.I., Lyall, R.A., Moxham, J. & Leigh, P.N. Respiratory aspects of
26 neurological disease. *Journal of Neurology, Neurosurgery & Psychiatry* **66**, 5-15
27 (1999).
- 28 111. Pollock, R.D., Rafferty, G.F., Moxham, J. & Kalra, L. Respiratory muscle strength
29 and training in stroke and neurology: a systematic review. *International Journal*
30 *of Stroke* **8**, 124-130 (2013).

- 1 112. Tian, C., Zhao, J., Xiong, Q., Yu, H. & Du, H. Secondary iron overload induces
2 chronic pancreatitis and ferroptosis of acinar cells in mice. *International Journal*
3 *of Molecular Medicine* **51**, 1-13 (2023).
- 4 113. Galaris, D., Barbouti, A. & Pantopoulos, K. Iron homeostasis and oxidative stress:
5 An intimate relationship. *Biochimica et Biophysica Acta (BBA)-Molecular Cell*
6 *Research* **1866**, 118535 (2019).
- 7 114. Robles, L., Vaziri, N.D. & Ichii, H. Role of oxidative stress in the pathogenesis of
8 pancreatitis: effect of antioxidant therapy. *Pancreatic disorders & therapy* **3**, 112
9 (2013).
- 10 115. Armstrong, J., *et al.* Oxidative stress in acute pancreatitis: lost in translation?
11 *Free radical research* **47**, 917-933 (2013).
- 12 116. Pérez, S., Pereda, J., Sabater, L. & Sastre, J. Redox signaling in acute pancreatitis.
13 *Redox biology* **5**, 1-14 (2015).
- 14 117. Kushner, T. & Cafardi, J. Chronic liver disease and COVID-19: alcohol use
15 disorder/alcohol-associated liver disease, nonalcoholic fatty liver
16 disease/nonalcoholic steatohepatitis, autoimmune liver disease, and
17 compensated cirrhosis. *Clinical Liver Disease* **15**, 195 (2020).
- 18 118. Grant, I., Heaton, R.K., McSweeney, A.J., Adams, K.M. & Timms, R.M. Brain
19 dysfunction in COPD. *Chest* **77**, 308-309 (1980).
- 20 119. Spilling, C.A., *et al.* Factors affecting brain structure in smoking-related diseases:
21 Chronic Obstructive Pulmonary Disease (COPD) and coronary artery disease.
22 *PLoS One* **16**, e0259375 (2021).
- 23 120. Kim, G.A., *et al.* Association between non-alcoholic fatty liver disease and the risk
24 of dementia: a nationwide cohort study. *Liver international* **42**, 1027-1036
25 (2022).
- 26 121. Kim, D.-G., *et al.* Non-alcoholic fatty liver disease induces signs of Alzheimer's
27 disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD
28 model. *Journal of neuroinflammation* **13**, 1-18 (2016).
- 29 122. Wang, L., Sang, B. & Zheng, Z. Risk of dementia or cognitive impairment in non-
30 alcoholic fatty liver disease: A systematic review and meta-analysis. *Frontiers in*
31 *Aging Neuroscience* **14**(2022).
- 32 123. Mobeen, S. & Apostol, R. Ovarian cyst. (2020).

- 1 124. Padda, J., *et al.* Depression and its effect on the menstrual cycle. *Cureus*
2 **13**(2021).
- 3 125. Azari, A.A. & Barney, N.P. Conjunctivitis: a systematic review of diagnosis and
4 treatment. *Jama* **310**, 1721-1730 (2013).
- 5 126. Sankowski, R., Mader, S. & Valdés-Ferrer, S.I. Systemic inflammation and the
6 brain: novel roles of genetic, molecular, and environmental cues as drivers of
7 neurodegeneration. *Frontiers in cellular neuroscience* **9**, 28 (2015).
- 8 127. Elwood, E., Lim, Z., Naveed, H. & Galea, I. The effect of systemic inflammation on
9 human brain barrier function. *Brain, behavior, and immunity* **62**, 35-40 (2017).
- 10 128. Rhyou, H.-I. & Nam, Y.-H. Association between cognitive function and asthma in
11 adults. *Annals of Allergy, Asthma & Immunology* **126**, 69-74 (2021).
- 12 129. Ray, M., Sano, M., Wisnivesky, J.P., Wolf, M.S. & Federman, A.D. Asthma control
13 and cognitive function in a cohort of elderly adults. *Journal of the American*
14 *Geriatrics Society* **63**, 684-691 (2015).
- 15 130. Alvarez, J.I., Cayrol, R. & Prat, A. Disruption of central nervous system barriers in
16 multiple sclerosis. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of*
17 *Disease* **1812**, 252-264 (2011).
- 18 131. Krupp, L.B., *et al.* International Pediatric Multiple Sclerosis Study Group criteria
19 for pediatric multiple sclerosis and immune-mediated central nervous system
20 demyelinating disorders: revisions to the 2007 definitions. *Multiple Sclerosis*
21 *Journal* **19**, 1261-1267 (2013).
- 22 132. Huda, S., *et al.* Neuromyelitis optica spectrum disorders. *Clinical Medicine* **19**,
23 169 (2019).
- 24 133. Kim, W., Kim, S.-H., Huh, S.-Y. & Kim, H.J. Brain abnormalities in neuromyelitis
25 optica spectrum disorder. *Multiple sclerosis international* **2012**(2012).
- 26 134. Lancaster, E. The diagnosis and treatment of autoimmune encephalitis. *Journal*
27 *of Clinical Neurology* **12**, 1-13 (2016).
- 28 135. Wartolowska, K., *et al.* Structural changes of the brain in rheumatoid arthritis.
29 *Arthritis & Rheumatism* **64**, 371-379 (2012).
- 30 136. Kozora, E. & Filley, C.M. Cognitive dysfunction and white matter abnormalities in
31 systemic lupus erythematosus. *Journal of the International Neuropsychological*
32 *Society* **17**, 385-392 (2011).

- 1 137. Appenzeller, S., *et al.* Longitudinal analysis of gray and white matter loss in
2 patients with systemic lupus erythematosus. *Neuroimage* **34**, 694-701 (2007).
- 3 138. Rosenberg, G.A. Inflammation and white matter damage in vascular cognitive
4 impairment. *Stroke* **40**, S20-S23 (2009).
- 5 139. Raj, D., *et al.* Increased white matter inflammation in aging-and Alzheimer's
6 disease brain. *Frontiers in molecular neuroscience* **10**, 206 (2017).
- 7 140. Gerdts, E., *et al.* Correlates of left atrial size in hypertensive patients with left
8 ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in
9 Hypertension (LIFE) Study. *Hypertension* **39**, 739-743 (2002).
- 10 141. Eshoo, S., Ross, D.L. & Thomas, L. Impact of mild hypertension on left atrial size
11 and function. *Circulation: Cardiovascular Imaging* **2**, 93-99 (2009).
- 12 142. Sanfilippo, A.J., *et al.* Atrial enlargement as a consequence of atrial fibrillation. A
13 prospective echocardiographic study. *Circulation* **82**, 792-797 (1990).
- 14 143. van de Vegte, Y.J., Siland, J.E., Rienstra, M. & van der Harst, P. Atrial fibrillation
15 and left atrial size and function: a Mendelian randomization study. *Scientific*
16 *reports* **11**, 8431 (2021).
- 17 144. Hiraiwa, H., *et al.* Clinical significance of spleen size in patients with heart failure.
18 *European Heart Journal* **42**, ehab724. 0756 (2021).
- 19 145. Ormazabal, V., *et al.* Association between insulin resistance and the
20 development of cardiovascular disease. *Cardiovascular diabetology* **17**, 1-14
21 (2018).
- 22 146. Shah, A., Mehta, N. & Reilly, M.P. Adipose inflammation, insulin resistance, and
23 cardiovascular disease. *Journal of Parenteral and Enteral Nutrition* **32**, 638-644
24 (2008).
- 25 147. Thurlbeck, W.M. & Müller, N. Emphysema: definition, imaging, and
26 quantification. *AJR. American journal of roentgenology* **163**, 1017-1025 (1994).
- 27 148. Fernández-García, V., González-Ramos, S., Martín-Sanz, P., Castrillo, A. & Boscá,
28 L. Contribution of extramedullary hematopoiesis to atherosclerosis. The spleen
29 as a neglected hub of inflammatory cells. *Frontiers in Immunology* **11**, 586527
30 (2020).
- 31 149. Suttorp, M. & Classen, C.F. Splenomegaly in children and adolescents. *Frontiers*
32 *in pediatrics*, 693 (2021).

- 1 150. Lampropoulos, C.E., Papaioannou, I. & D'cruz, D.P. Osteoporosis—a risk factor
2 for cardiovascular disease? *Nature Reviews Rheumatology* **8**, 587-598 (2012).
- 3 151. Gaines, J.M., *et al.* Older men's knowledge of osteoporosis and the prevalence of
4 risk factors. *Journal of Clinical Densitometry* **13**, 204-209 (2010).
- 5 152. Whalen, R., Carter, D. & Steele, C. Influence of physical activity on the regulation
6 of bone density. *Journal of biomechanics* **21**, 825-837 (1988).
- 7 153. Zhao, Q., Wang, J., Spiller, W., Bowden, J. & Small, D.S. Two-sample instrumental
8 variable analyses using heterogeneous samples. *Statistical Science* **34**, 317-333
9 (2019).
- 10 154. Cui, R., *et al.* Improving fine-mapping by modeling infinitesimal effects. *bioRxiv*,
11 2022.2010. 2021.513123 (2022).
- 12 155. Xue, H., Shen, X. & Pan, W. Causal Inference in Transcriptome-Wide Association
13 Studies with Invalid Instruments and GWAS Summary Data. *Journal of the*
14 *American Statistical Association*, 1-27 (2023).
- 15 156. Tseng, W.Y., Su, M.Y. & Tseng, Y.H. Introduction to Cardiovascular Magnetic
16 Resonance: Technical Principles and Clinical Applications. *Acta Cardiol Sin* **32**,
17 129-144 (2016).
- 18 157. Pennell, D.J. Cardiovascular magnetic resonance. *Circulation* **121**, 692-705
19 (2010).
- 20 158. Bai, W., *et al.* Automated cardiovascular magnetic resonance image analysis with
21 fully convolutional networks. *Journal of Cardiovascular Magnetic Resonance* **20**,
22 1-12 (2018).
- 23 159. Bai, W., *et al.* Recurrent neural networks for aortic image sequence
24 segmentation with sparse annotations. *International conference on medical*
25 *image computing and computer-assisted intervention*, 586-594 (2018).
- 26 160. Miller, K.L., *et al.* Multimodal population brain imaging in the UK Biobank
27 prospective epidemiological study. *Nat Neurosci* **19**, 1523-1536 (2016).
- 28 161. Zhao, B., *et al.* Heritability of regional brain volumes in large-scale neuroimaging
29 and genetic studies. *Cerebral Cortex* **29**, 2904-2914 (2019).
- 30 162. Zhao, B., *et al.* Large-scale GWAS reveals genetic architecture of brain white
31 matter microstructure and genetic overlap with cognitive and mental health
32 traits (n= 17,706). *Molecular psychiatry* **26**, 3943-3955 (2021).

- 1 163. Avants, B.B., *et al.* A reproducible evaluation of ANTs similarity metric
2 performance in brain image registration. *Neuroimage* **54**, 2033-2044 (2011).
- 3 164. Jahanshad, N., *et al.* Multi-site genetic analysis of diffusion images and voxelwise
4 heritability analysis: A pilot project of the ENIGMA-DTI working group.
5 *Neuroimage* **81**, 455-469 (2013).
- 6 165. Kochunov, P., *et al.* Multi-site study of additive genetic effects on fractional
7 anisotropy of cerebral white matter: comparing meta and megaanalytical
8 approaches for data pooling. *Neuroimage* **95**, 136-150 (2014).
- 9 166. Glasser, M.F., *et al.* A multi-modal parcellation of human cerebral cortex. *Nature*
10 **536**, 171-178 (2016).
- 11 167. Ji, J.L., *et al.* Mapping the human brain's cortical-subcortical functional network
12 organization. *Neuroimage* **185**, 35-57 (2019).
- 13 168. Bowden, J., *et al.* Improving the accuracy of two-sample summary-data
14 Mendelian randomization: moving beyond the NOME assumption. *International*
15 *journal of epidemiology* **48**, 728-742 (2019).

16

17 **METHODS**

18 **Multi-organ imaging biomarkers.**

19 The imaging data were sourced from the UK Biobank (UKB) study, which enrolled
20 approximately 500,000 individuals aged between 40 and 69 from 2006 to 2010
21 (<https://www.ukbiobank.ac.uk/>). These multi-organ imaging data were collected from
22 the ongoing UKB imaging study project ([https://www.ukbiobank.ac.uk/explore-your-
23 participation/contribute-further/imaging-study](https://www.ukbiobank.ac.uk/explore-your-participation/contribute-further/imaging-study)), which aims to collect brain, heart, and
24 abdomen scans from 100,000 participants. Ethical approval for the UKB study was
25 secured from the North West Multicentre Research Ethics Committee (approval number:
26 11/NW/0382).

27

28 Studies of brain and heart diseases usually rely on magnetic resonance imaging (MRI)
29 scans, which are well-established clinical endophenotypes. Cardiovascular magnetic
30 resonance imaging (CMR) is a set of MRI techniques that are designed to assess
31 ventricular function, cardiovascular morphology, myocardial perfusion, and other cardiac
32 functional and structural features^{156,157}. They have been frequently used to reveal heart-

1 related issues clinically. The CMR traits used in the paper were originally generated from
2 the raw short-axis, long-axis, and aortic cine images using the state-of-the-art heart
3 imaging segmentation and feature representation framework^{38,158,159}. We divided the
4 generated 82 CMR traits into 6 categories. The first two are aortic sections, namely
5 ascending aorta (AAo) and descending aorta (DAo), which serve as the main ‘pipe’ in
6 supplying blood to the entire body. The other four are the global measures of 4 cardiac
7 chambers, including the left ventricle (LV), right ventricle (RV), left atrium (LA), and right
8 atrium (RA), which altogether manage the heartbeat and blood flow. There are also some
9 other traits, such as regional phenotypes of the left ventricle myocardial-wall thickness
10 and strain (**Table S1**). The summary-level GWAS data of these 82 CMR traits were
11 obtained from Zhao, et al.³⁹.

12

13 Brain MRI provides detailed information about brain structure and function¹⁶⁰, such as
14 abnormal growth, healthy aging, white matter diseases, structural issues, and functional
15 abnormalities. In this paper, the summary-level GWAS data were collected from recent
16 multi-modal image genetic studies, including regional brain volumes from structural
17 MRI^{21,161} (sMRI), diffusion tensor imaging (DTI) parameters from diffusion MRI^{23,162} (dMRI),
18 and functional activity (that is, amplitude³⁷) and functional connectivity phenotypes from
19 resting functional MRI²⁵ (resting fMRI). In sMRI, we used ANTs¹⁶³ to generate regional
20 brain volumes for cortical and subcortical regions and global brain volume measures. In
21 dMRI, we used the ENIGMA-DTI pipelines^{164,165} to generate tract-averaged parameters
22 for fractional anisotropy, mean diffusivity, axial diffusivity, radial diffusivity, and mode of
23 anisotropy in major white matter tracts and across the whole brain. For resting fMRI, we
24 extracted phenotypes from brain parcellation-based analysis. We used the Glasser360
25 atlas¹⁶⁶, which divided the cerebral cortex into 360 regions in 12 functional networks¹⁶⁷.
26 We considered 90 network-level resting fMRI phenotypes that evaluated interactions and
27 spontaneous neural activity at rest.

28

29 The 11 imaging biomarkers from abdominal MRI were derived by Liu., et al⁸ using deep
30 learning methods in terms of volume, fat, and iron in several organs and tissues, such as
31 the liver, spleen, kidney, lung, pancreas, and adipose tissue. Skeleton DXA traits, including
32 all long bone lengths as well as hip and shoulder width, were derived by Kun., et al³ using

1 deep learning methods on whole-body dual-energy X-ray absorptiometry (DXA) images.
2 All eight skeleton traits have been controlled for height. The heritability of the above
3 imaging biomarkers can be found in **Supplementary Note**.

4 5 **FinnGen clinical endpoints.**

6 We used 88 clinical endpoints collected by the FinnGen project, which were selected from
7 the R7 release and with more than 10,000 cases for most of the clinical endpoints
8 (https://www.finnngen.fi/en/access_results). As for some important diseases, such as
9 Alzheimer's disease, we set the cutoff of the number of cases to be 6,000. The 88 clinical
10 endpoints covered diseases from various categories, namely, mental and behavioral
11 disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the
12 genitourinary system, diseases of the circulatory systems, cardiometabolic endpoints,
13 diseases marked as autoimmune origin, rheuma endpoints, interstitial lung diseases,
14 COPD and related endpoints, as well as some unclassified endpoints. The definitions can
15 be found at <https://risteys.finregistry.fi/>. The FinnGen data used in our study was
16 obtained from separate cohorts than those supplying imaging biomarkers, which were
17 derived from the UKB study, thus ensuring there was no sample overlap. Detailed
18 information of these 88 clinical variables can be found in **Table S2**.

19 20 **Mendelian randomization analysis.**

21 We examined the genetic causal relationships between the 402 imaging biomarkers (101
22 brain regional volume traits, 110 brain DTI parameters, 90 network-level fMRI phenotypes,
23 82 CMR traits, 11 abdominal traits, and 8 skeleton DXA traits) and 88 clinical endpoints.
24 Prior to conducting the Mendelian randomization (MR) analysis, we conducted standard
25 preprocessing and quality control procedures. First, we selected genetic variants based
26 on a significance threshold of 5×10^{-8} in the exposure GWAS data. To ensure the
27 independence of the genetic variants used in MR, we implemented LD clumping with a
28 window size of 10,000 and an r^2 threshold of 0.01, using the 1000 Genomes European
29 ancestry data as a reference panel. We used the TwoSampleMR package
30 (<https://mrcieu.github.io/TwoSampleMR/>) for harmonization, which enabled us to
31 accurately align alleles between the selected variants in the exposure and the reported
32 effect on the outcome.

1

2 We assessed the performance of 8 MR methods, which included Inverse variance
3 weighted (fixed effect), Inverse variance weighted (multiplicative random effect), MR-
4 Egger, Simple Median, Weighted Median, Weighted Mode, DIVW, GRAPPLE, and MR-
5 RAPS^{40,41,43-48,168}, where MR Egger was used as the pleiotropy test. To ensure the reliability
6 of our results, we implemented several quality control procedures. We excluded causal
7 estimates that relied on fewer than 6 genetic variants, as a larger number of genetic
8 variants increases the statistical power of MR analysis^{46,47}. We retained causal pairs that
9 were significant in at least two out of the eight methods. We also screened for pleiotropy
10 by using the MR-Egger intercept, the most used method for testing the pleiotropy
11 assumption. If a causal estimate failed the MR-Egger intercept test, we required that it
12 have significant results in at least one of the robust MR methods, such as Weighted
13 Median, Weighted Model, MR-RAPS, or GRAPPLE. Out of 488 significant findings, 81
14 causal estimates failed the MR-Egger intercept test. However, when we interpreted the
15 results, we focused on the ones that passed the MR-Egger intercept test.

16

17 **Code availability**

18 We made use of publicly available software and tools. Our analysis code will be made
19 freely available at Zenodo.

20

21 **Data availability**

22 We used summary-level GWAS data in this study, which can be obtained from the
23 FinnGen project (https://www.finnngen.fi/en/access_results), BIG-KP (<https://bigkp.org/>),
24 Heart-KP (<https://heartkp.org/>), and project-specific resources detailed in Liu., et al⁸ and
25 Kun., et al³. Our multi-organ MR results can be explored at <https://mr4mo.org/>.

26

27 **Figure legends**

28

29 **Fig. 1 Overview of study design and findings.**

30 (A). An overview of our multi-organ imaging genetic study, investigating 88 clinical
31 outcomes. We employed diverse imaging biomarkers including multi-modal brain,

1 cardiac, abdominal, and skeletal DXA imaging to explore their relationships with the
2 clinical endpoints. Our study encompasses a comprehensive range of brain imaging
3 modalities, such as structural MRI, diffusion MRI, and resting-state fMRI. The cardiac
4 imaging data comprise short-axis, long-axis, and aortic cine images. Volume, iron content,
5 and percent fat were measured across 6 different abdominal organs and tissues, yielding
6 in 11 image-derived abdominal phenotypes. Additionally, we included 8 skeleton imaging
7 biomarkers encompassing long bone lengths as well as hip and shoulder width. **(B)**. A high-
8 level summary of our bidirectional findings. The left panel displayed all the imaging
9 biomarkers that have been used in the study. The grey arrow demonstrates the main
10 findings, such as the intra-brain, intra-heart, brain-heart, and brain-abdominal-organs
11 causal connections. The right panel depicts the intricate web of causal interactions among
12 various organs as uncovered in our study. Blue arrows signify causal relationships that
13 involve either the heart or brain, while orange arrows represent causal connections that
14 do not include the heart or brain. The width of an arrow corresponds to the volume of
15 findings associated with it.

16

17 **Fig. 2 Selected genetic causal effects of clinical outcomes on brain imaging biomarkers.**

18 We illustrated selected significant ($P < 5.18 \times 10^{-6}$) causal genetic links from clinical
19 endpoints (Exposure) to brain imaging biomarkers (Outcome), with adjustment for
20 multiple testing using the Bonferroni procedure. **(A)**. The causal effect of Alzheimer's
21 disease on brain imaging biomarkers. **(B)**. The causal effect of dementia on brain imaging
22 biomarkers. **(C)**. The causal effect of hypertension on brain imaging biomarkers. The
23 term 'IDP Category' is used to signify the category of imaging biomarkers, while '#IVs'
24 stands for the number of genetic variants utilized as instrumental variables. Various MR
25 methods and their associated regression coefficients are marked with different colors for
26 easy identification. See **Table S1** for data resources of clinical endpoints and **Table S2** for
27 data resources of imaging biomarkers.

28

29 **Fig. 3 Selected genetic causal effects of brain imaging biomarkers on clinical endpoints.**

30 We illustrated selected significant ($P < 5.18 \times 10^{-6}$) causal genetic links from brain imaging
31 biomarkers (Exposure) to clinical endpoints (Outcome), with adjustment for multiple

1 testing using the Bonferroni procedure. **(A)**. The causal effect of brain imaging biomarkers
2 on Alzheimer's diseases. **(B)**. The causal effect of brain imaging biomarkers on dementia.
3 The term 'IDP Category' is used to signify the category of imaging biomarkers, while '#IVs'
4 stands for the number of genetic variants utilized as instrumental variables. Various MR
5 methods and their associated regression coefficients are marked with different colors for
6 easy identification. See **Table S1** for data resources of clinical endpoints and **Table S2** for
7 data resources of imaging biomarkers.

8

9 **Fig. 4 Selected genetic causal effects between heart imaging biomarkers and clinical**
10 **endpoints.**

11 **(A)**. Selected significant ($P < 6.85 \times 10^{-6}$) causal genetic links from clinical endpoints
12 (Exposure) to heart imaging biomarkers (Outcome) with adjustment for multiple testing
13 using the Bonferroni procedure. **(B-C)**. The heart diagram shows the region of the
14 corresponding IDP when hypertensive diseases and hypertension are the exposure
15 variables. **(D)**. Selected significant ($P < 6.85 \times 10^{-6}$) causal genetic links from heart imaging
16 biomarkers (Exposure) to clinical endpoints (Outcome) with adjustment for multiple
17 testing using the Bonferroni procedure. **(E-G)**. The heart diagram shows the region of the
18 corresponding IDP when atrial fibrillation and flutter, heart failure and antihypertensive
19 medication, as well as hypertension, are the outcome variables. The term 'IDP Category'
20 is used to signify the category of imaging biomarkers, while '#IVs' stands for the number
21 of genetic variants utilized as instrumental variables. Various MR methods and their
22 associated regression coefficients are marked with different colors for easy identification.
23 See **Table S1** for data resources of clinical endpoints and **Table S2** for data resources of
24 imaging biomarkers.

25

26 **Fig. 5 Selected genetic causal effects between abdominal imaging biomarkers and**
27 **clinical endpoints.**

28 We illustrated selected significant ($P < 6.69 \times 10^{-5}$) causal genetic links from **(A)** clinical
29 endpoints (Exposure) to abdominal imaging biomarkers (Outcome) and **(B)** abdominal
30 imaging biomarkers (Exposure) to clinical endpoints (Outcome) with adjustment for
31 multiple testing using the Bonferroni procedure. The term 'IDP Category' is used to signify

1 the category of imaging biomarkers, while '#IVs' stands for the number of genetic variants
2 utilized as instrumental variables. Various MR methods and their associated regression
3 coefficients are marked with different colors for easy identification. **(C-F)**. Selected causal
4 associations between abdominal imaging biomarkers and multi-organ diseases. See **Table**
5 **S1** for data resources of clinical endpoints and **Table S2** for data resources of imaging
6 biomarkers.

7

8 **Fig. 6 Selected genetic causal effects between skeleton imaging biomarkers and clinical**
9 **endpoints.**

10 We illustrated selected significant ($P < 3.39 \times 10^{-5}$) causal genetic links from **(A)** clinical
11 endpoints to (Exposure) to skeleton imaging biomarkers (Outcome) and **(B)** skeleton
12 imaging biomarkers (Exposure) to clinical endpoints (Outcome) with adjustment for
13 multiple testing using the Bonferroni procedure. The term 'IDP Category' is used to signify
14 the category of imaging biomarkers, while '#IVs' stands for the number of genetic variants
15 utilized as instrumental variables. Various MR methods and their associated regression
16 coefficients are marked with different colors for easy identification. The skeleton diagram
17 on the right shows the region of the corresponding IDP. See **Table S1** for data resources
18 of clinical endpoints and **Table S2** for data resources of imaging biomarkers.

19




Figure 1




Figure 2







Figure 3




B Hypertensive disease to heart imaging biomarkers




C Hypertension to heart imaging biomarkers



E Heart imaging biomarkers to atrial fibrillation and flutter



F Heart imaging biomarkers to heart failure and antihypertensive medication



G Heart imaging biomarkers to hypertension




Figure 4




Figure 5




Figure 6